Discontinued — last reported Q1 '26
Business Segments · Other adjustments
U.S. Pharmaceutical — Other adjustments
McKesson U.S. Pharmaceutical — Other adjustments increased by 262.5% to $29.00M in Q2 2025 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryOther
SignalLower is better
VolatilityVolatile
First reportedQ1 2020
Last reportedQ1 2026Aug 6, 2025
Rolls up toPurchase Price Adjustments
How to read this metric
High levels of adjustments may indicate significant restructuring or one-time events that obscure core operational performance.
Detailed definition
Captures non-recurring or non-operational items specific to the U.S. Pharmaceutical segment that do not fit into standar...
Peer comparison
Standard line item in segment reporting to reconcile GAAP operating profit to adjusted segment performance.
Metric ID:
mck_segment_u_s_pharmaceutical_other_adjustmentsHistorical Data
7 periods
| Q1 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | -$3.00M | -$10.00M | -$5.00M | -$2.00M | $0.00 | $8.00M | $29.00M |
| QoQ Change | — | -233.3% | +50.0% | +60.0% | +100.0% | — | +262.5% |
| YoY Change | — | — | -66.7% | — | — | — | — |
Range-$10.00M – $29.00M
CAGR+353.8%
Avg YoY Growth-66.7%
Median YoY Growth-66.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — other adjustments?
- McKesson (MCK) reported u.s. pharmaceutical — other adjustments of $29.00M in Q2 2025.
- What does u.s. pharmaceutical — other adjustments mean?
- Miscellaneous non-recurring financial adjustments specific to the U.S. Pharmaceutical segment.